Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology

被引:329
|
作者
O'Banion, MK
机构
[1] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Dept Neurobiol & Anat, Rochester, NY 14642 USA
来源
CRITICAL REVIEWS IN NEUROBIOLOGY | 1999年 / 13卷 / 01期
关键词
prostaglandin; phospholipase A(2); neurons; glia; nonsteroidal antiinflammatory drugs (NSAIDs); hyperalgesia; seizure; stroke; Alzheimer's disease;
D O I
10.1615/CritRevNeurobiol.v13.i1.30
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In the nervous system, prostanoids are well recognized as mediators in a variety of processes, including fever generation, modulation of the stress response, sleep/wake cycle, control of cerebral blood flow, and hyperalgesia. Two isoforms of cyclooxygenase (COX), the enzyme that catalyzes the conversion of arachidonic acid to prostanoids, are now recognized: a constitutively expressed COX-1 and a highly regulated COX-2. New molecular and pharmacologic tools have provided a better understanding of the roles of COX-generated prostanoids in the nervous system. Other studies reveal that COX may represent an important target for new therapeutic approaches to neurologic disorders. This review summarizes our current understanding of cyclooxygenase expression and prostanoid actions in the nervous system, with special reference to COX-2 and studies demonstrating its expression in different cell types responding to a variety of stimuli. A brief review of the molecular biology, pharmacology, and primary actions of COX-2 outside of the nervous system provides a context for understanding potential neurobiological roles for COX-2 and prostanoid production. Information about the role of COX in human neurological disorders, including cerebrovascular disease, Alzheimer's disease, and hyperalgesia, is covered in the last section.
引用
收藏
页码:45 / 82
页数:38
相关论文
共 50 条
  • [31] Molecular model of the interaction between nimesulide and human cyclooxygenase-2
    García-Nieto, R
    Pérez, C
    Checa, A
    Gago, F
    RHEUMATOLOGY, 1999, 38 : 14 - 18
  • [32] Molecular characterization of cyclooxygenase-2 in a stimulated prostate stroma cells
    Lin, VK
    Wang, SY
    Roehrborn, CG
    JOURNAL OF UROLOGY, 2006, 175 (04): : 467 - 467
  • [33] Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An update on the molecular mechanisms
    Wu, William Ka Kei
    Sung, Joseph Jao Yiu
    Lee, Chung Wa
    Yu, Jun
    Cho, Chi Hin
    CANCER LETTERS, 2010, 295 (01) : 7 - 16
  • [34] Selective cyclooxygenase-2 inhibitor. Pharmacology and state of knowledge following commercial availability
    Schmidt, H
    Geisslinger, G
    SCHMERZ, 2001, 15 (03): : 207 - 219
  • [35] Pharmacology and Gastrointestinal Safety of Lumiracoxib, a Novel Cyclooxygenase-2 Selective Inhibitor: An Integrated Study
    Atherton, Clare
    Jones, John
    McKaig, Brian
    Bebb, James
    Cunliffe, Rob
    Burdsall, Jake
    Brough, Joanne
    Stevenson, Diane
    Bonner, Johanne
    Rordorf, Christiane
    Scott, Graham
    Branson, Janice
    Hawkey, Christopher J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (02) : 113 - 120
  • [36] Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology
    Hinz, Burkhard
    Brune, Kay
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (08) : 391 - 397
  • [37] Pharmacology of Cannabinoid Receptor Agonists and a Cyclooxygenase-2 Inhibitor in Rat Bone Tumor Pain
    Cui, Jin Hua
    Ju, Jin
    Yoon, Myung Ha
    PHARMACOLOGY, 2013, 92 (3-4) : 150 - 157
  • [38] NEUROBIOLOGY AND MOLECULAR-BIOLOGY - THE 2ND ENCOUNTER
    KANDEL, ER
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1983, 48 : 891 - 908
  • [39] Cyclooxygenase-2 and inflammation in atherosclerosis
    Linton, MF
    Fazio, S
    CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (02) : 116 - 123
  • [40] Alternative polyadenylation of cyclooxygenase-2
    Hall-Pogar, T
    Zhang, H
    Tian, B
    Lutz, CS
    NUCLEIC ACIDS RESEARCH, 2005, 33 (08) : 2565 - 2579